- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Invitation - Orexo Capital Markets Day, Stockholm, Sweden, March 17 | 255 | PR Newswire | UPPSALA, Sweden, Feb. 19, 2020 /PRNewswire/ -- Orexo AB (publ.), today invites investors, analysts and media to attend the company's Capital Markets Day, taking place in Stockholm, Sweden... ► Artikel lesen | |
| OREXO Aktie jetzt für 4€ handeln | |||||
| 17.02. | Orexo AB (publ.) has Resolved to Carry out Repurchases of own Shares | 136 | PR Newswire | UPPSALA, Sweden, Feb. 17, 2020 /PRNewswire/ -- The board of Orexo AB (publ.) has resolved, pursuant to the authorisation granted by the annual general meeting held on 11 April 2019, to initiate... ► Artikel lesen | |
| 06.02. | Orexo - Zubsolv stabilizing enables R&D push | 96 | Edison Investment Research | Orexo continues to weather the shift in its payer base away from exclusivity to the open market well. It has managed to maintain 4% sequential growth in Zubsolv sales from Q3 to Q419 (SEK190.5m), in... ► Artikel lesen | |
| 30.01. | OREXO: Q4 incl. Full Year Report 2019 | 3 | Cision News | ||
| 29.01. | OREXO: Promising results from human PK study assessing novel ketorolac formulations for treatment of pain | - | Cision News | ||
| 03.12.19 | Save the Date: Orexo to Host Capital Markets Day focusing on Digital Health, on March 17, 2020 | 199 | PR Newswire | UPPSALA, Sweden, Dec. 3, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company with the aim of becoming a leader in the treatment of addiction, today... ► Artikel lesen | |
| 02.12.19 | Orexo Appoints Dennis Urbaniak as Executive Vice President Digital Health | 192 | PR Newswire | - Appointment strengthens Orexo's competencies and resources within digital health
- Orexo committed to finding innovative solutions to improve treatment of addiction
UPPSALA, Sweden... ► Artikel lesen | |
| 27.11.19 | Orexo Acquires Exclusive US Rights to Commercialize Vorvida, a Digital Therapy for Alcohol Use Disorder with Scientifically Proven Efficacy | 279 | PR Newswire | -Deal further strengthens Orexo's partnership with GAIA
-Orexo committed to digital health to address addiction
UPPSALA, Sweden, Nov. 27, 2019 /PRNewswire/ -- Orexo AB (publ)... ► Artikel lesen | |
| 21.11.19 | Orexo AB ADR (ORXOY) Presents At Jefferies Global Healthcare Conference - Slideshow | - | Seeking Alpha | ||
| 08.11.19 | Orexo to Present at Jefferies 2019 Healthcare Conference | 202 | PR Newswire | UPPSALA, Sweden , Nov. 8, 2019 /PRNewswire/ -- Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company... ► Artikel lesen | |
| 31.10.19 | Orexo - Record quarter reflecting shifting US market | 156 | Edison Investment Research | Orexo reported a record performance for Q319 with revenue of SEK231.2m (+6.7% year-on-year). The top line was lifted by a combination of factors including currency and a shift in the reimbursement landscape... ► Artikel lesen | |
| 24.10.19 | Orexo AB reports Q3 results | 2 | Seeking Alpha | ||
| 24.10.19 | Orexo Interim Report Q3 2019 | 266 | PR Newswire | Orexo Interim Report Q3 2019
PR Newswire
UPPSALA, Sweden, Oct. 24, 2019
Strong financials paving the way for broadening the business
UPPSALA, Sweden, Oct. 24, 2019... ► Artikel lesen | |
| 14.10.19 | Orexo's Nomination Committee for the Annual General Meeting 2020 | 291 | PR Newswire | UPPSALA, Sweden, Oct. 14, 2019 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2020, Orexo has appointed a Nomination Committee which represents approximately 44 percent of the... ► Artikel lesen | |
| 21.08.19 | Orexo - Bringing AI to the treatment of OUD | 177 | Edison Investment Research | Orexo has announced a partnership for the digital therapy of opioid use disorder (OUD) with GAIA, a global leader in digital therapeutics. The partnership will use GAIA's expert system technology platform... ► Artikel lesen | |
| 20.08.19 | Orexo Signs Partnership Agreement With GAIA AG to Develop and Commercialize a new Digital Therapy for the Treatment of Opioid Use Disorder | 410 | PR Newswire | UPPSALA, Sweden, Aug. 20, 2019 /PRNewswire/ -- Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces it has entered into... ► Artikel lesen | |
| 15.07.19 | Orexo - By leaps and bounds | 63 | Edison Investment Research | After a strong Q119, which is seasonally the weakest quarter, Orexo also had a higher bar to beat Q218 due to milestone income making it one of its best ever quarters. Nevertheless, total Q219 revenues... ► Artikel lesen | |
| 11.07.19 | Orexo Interim Report Q2 2019 | 76 | PR Newswire | Improving all fundamentals
UPPSALA, Sweden, July 11, 2019 /PRNewswire/ --
Q2 2019 highlights
Total net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1... ► Artikel lesen | |
| 10.07.19 | Orexo Signs License and Supply Agreement With Mundipharma for Zubsolv in Australia and New Zealand | 73 | PR Newswire | UPPSALA, Sweden, July 10, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces the company has... ► Artikel lesen | |
| 09.07.19 | Orexo Prepays Part of the Corporate Bond Loan | 66 | PR Newswire | UPPSALA, Sweden , July 9, 2019 /PRNewswire/ --Orexo AB (publ.) has resolved to prepay SEK 32.5 million, corresponding to 10 percent, of the unsecured corporate bond loan of in total SEK 325... ► Artikel lesen |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEVA | 11,660 | -4,11 % | TEVA Pharmaceutical: Neues Kursziel | Zürich (www.aktiencheck.de) - Rating-Update: Kevin Caliendo, Analyst der UBS, stuft die Aktie des Biotechkonzerns TEVA Pharmaceutical Industries Ltd. (ISIN: US8816242098, WKN: 883035, Ticker-Symbol:... ► Artikel lesen | |
| BAUSCH HEALTH | 23,810 | -2,54 % | Bausch Health Americas, Inc. -- Moody's assigns Ba2 to Bausch Health's credit facility | ||
| EYEPOINT PHARMACEUTICALS | 1,330 | 0,00 % | Why EyePoint Pharmaceuticals Is Cratering Today | ||
| WAYLAND GROUP | 0,480 | +3,25 % | DGAP-News: Wayland Group Corporation: Wayland berichtet über den aktuellen Stand der Transaktion, der Konstruktionsarbeiten und den betrieblichen Fortschritt (deutsch) | Wayland Group Corporation: Wayland berichtet über den aktuellen Stand der Transaktion, der Konstruktionsarbeiten und den betrieblichen Fortschritt
DGAP-News: Wayland Group Corporation / Schlagwort(e):
Unternehmensrestrukturierung
Wayland... ► Artikel lesen | |
| DERMAPHARM | 39,920 | -3,70 % | Dermapharm kauft Merck-Tochter Allergopharma | Die Dermapharm Holding übernimmt die Allergopharma GmbH & Co. KG mit Sitz in Reinbek bei Hamburg. Ein Vertrag zur Übernahme der Gesellschaft sei heute abgeschlossen worden, meldet das börsennotierte... ► Artikel lesen | |
| CATABASIS PHARMACEUTICALS | 4,780 | -6,27 % | Die Katastrophe heißt Catabasis - Der Experte verrät jetzt warum es noch viel tiefer gehen wird | ||
| EDWARDS LIFESCIENCES | 209,15 | -1,88 % | Problem Zivilisationskrankheiten? Eher nicht für Aktionäre von Edwards Lifesciences... | Die Menschen werden immer älter, obwohl sie sich seltener bewegen und die Kalorienzufuhr ständig steigt. Kein Wunder, dass Erkrankungen des Herz-Kreislauf-Systems zu den häufigsten Todesursachen und... ► Artikel lesen | |
| AMARIN | 15,700 | -4,85 % | Amarin Q4 2019 Earnings Preview | ||
| INVIVO THERAPEUTICS HOLDINGS | 5,920 | -6,48 % | INVIVO THERAPEUTICS HOLDINGS CORP. - S-1, General form for registration of securities | ||
| MALLINCKRODT | 3,620 | -23,39 % | Mallinckrodt Considers Bankruptcy Over Opioid Lawsuits | ||
| ENDO | 5,614 | +0,25 % | Endo Appoints Mark G. Barberio to Board of Directors | DUBLIN, Feb. 19, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Mark G. Barberio to serve as a director, effective... ► Artikel lesen | |
| ERGOMED | 4,960 | -4,62 % | Asarina Pharma issues new shares to Ergomed plc | ||
| ARENA PHARMACEUTICALS | 49,400 | 0,00 % | Mit der Teilnahme am Kongress der Europäischen Crohn- und Colitis-Organisation (ECCO) unterstreicht Arena Pharmaceuticals sein Engagement für Betroffene von GI-Erkrankungen | San Diego (ots/PRNewswire) - - Neue Biomarkerdaten aus der offenen Verlängerungsstudie (open-label extension; OLE) der Phase-2-OASIS-Studie mit Etrasimod für Patienten mit mäßig bis stark aktiver Colitis... ► Artikel lesen | |
| INSYS THERAPEUTICS | 0,042 | +5,00 % | XFRA NPR1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL INSYS THERAPEUT.DL-... ► Artikel lesen | |
| GLOBAL HEALTH CLINICS | 0,009 | -11,32 % | Global Health Clinics Ltd: Global Health appoints Hill director of patient care |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
